Table 4. % ID g−1 of tumour and tumour/normal tissue ratios for MAb 35A7 conjugates.
|
Ratio
|
|||||
|---|---|---|---|---|---|
| Conjugate+DOL | % ID g−1 tumour | Tumour/blood | Tumour/muscle | Tumour/colon | Tumour/small int. |
| PS 1 (1.4) | 17.3±1.1 | 1.1±0.1 | 15.6±0.7 | 22.1±1.7 | 16.7±1.3 |
| PS 1 (1.6) | 23.3±12.8 | 1.5±0.7 | 16.8±10.0 | 29.4±15.9 | 18.8±12.3 |
| PS 1 (2.0) | 31.8±±7.0 | 1.8±0.1 | 18.5±2.8 | 33.3±5.0 | 23.0±3.2 |
| PS 2 (1.6) | 23.9±3.4 | 2.1±0.2 | 24.9±3.4 | 33.5±3.8 | 26.3±5.2 |
| PS 2 (2.3) | 17.4±6.2 | 1.9±0.7 | 19.8±6.0 | 25.1±10.3 | 14.8±12.2 |
| PS 2 (2.5) | 12.9±4.2 | 1.9±0.6 | 16.6±5.6 | 18.7±5.3 | 13.4±4.7 |
% ID g−1=percent of injected dose per gram of tissue; MAb=monoclonal antibodies; DOL=degree of labeling; PS=photosensitisers. Values were obtained 24 h postinjection (values are the means of tumour/normal ratios and % ID g−1 tumour±s.d. calculated from the three mice bearing the LS174T xenograft in each conjugate group).